Emerson S Bernardes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2408656/publications.pdf

Version: 2024-02-01

43 papers 1,167 citations

³⁹⁴⁴²¹
19
h-index

33 g-index

43 all docs 43 docs citations

43 times ranked 1831 citing authors

#	Article	IF	CITATIONS
1	Knee radiosynovectomy with 153Sm-hydroxyapatite compared to 90Y-hydroxyapatite: initial results of a prospective trial. Annals of Nuclear Medicine, 2021, 35, 232-240.	2.2	3
2	Engineering of galectin-3 for glycan-binding optical imaging. Biochemical and Biophysical Research Communications, 2020, 521, 674-680.	2.1	3
3	Galectins in Host Defense Against Microbial Infections. Advances in Experimental Medicine and Biology, 2020, 1204, 141-167.	1.6	19
4	Galectin-3 Regulates the Expression of Tumor Glycosaminoglycans and Increases the Metastatic Potential of Breast Cancer. Journal of Oncology, 2019, 2019, 1-15.	1.3	20
5	Colorectal Adenocarcinoma: Imaging using 5-Fluoracil Nanoparticles Labeled with Technetium 99 Metastable. Current Pharmaceutical Design, 2019, 25, 3282-3288.	1.9	2
6	Lack of galectin-3 modifies differentially Notch ligands in bone marrow and spleen stromal cells interfering with B cell differentiation. Scientific Reports, 2018, 8, 3495.	3.3	16
7	Diagnosing lung cancer using etoposide microparticles labeled with ^{99m} Tc. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 341-345.	2.8	19
8	<i>In loco</i> retention effect of magnetic core mesoporous silica nanoparticles doped with trastuzumab as intralesional nanodrug for breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 725-733.	2.8	8
9	Nanoradiopharmaceuticals in current molecular medicine. , 2018, , 553-569.		2
10	Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations. International Journal of Nanomedicine, 2017, Volume 12, 53-60.	6.7	30
11	MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2495-2505.	3.3	91
12	Isolation and partial characterization of 3 nontoxic <scp>d</scp> â€galactose–specific isolectins from seeds of <scp><i>Momordica balsamina</i></scp> . Journal of Molecular Recognition, 2017, 30, e2582.	2.1	6
13	Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation. Oncotarget, 2017, 8, 49484-49501.	1.8	65
14	Nanoradiopharmaceuticals for breast cancer imaging: development, characterization, and imaging in inducted animals. OncoTargets and Therapy, 2016, Volume 9, 5847-5854.	2.0	14
15	Larval application of sodium channel homologous dsRNA restores pyrethroid insecticide susceptibility in a resistant adult mosquito population. Parasites and Vectors, 2016, 9, 397.	2.5	35
16	The deficiency of galectin-3 in stromal cells leads to enhanced tumor growth and bone marrow metastasis. BMC Cancer, 2016, 16, 636.	2.6	14
17	Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies. Journal of Drug Delivery Science and Technology, 2016, 36, 95-98.	3.0	8
18	Lack of galectin-3 increases Jagged1/Notch activation in bone marrow-derived dendritic cells and promotes dysregulation of T helper cell polarization. Molecular Immunology, 2016, 76, 22-34.	2.2	22

#	Article	IF	CITATIONS
19	Lack of galectin-3 up-regulates IgA expression by peritoneal B1 lymphocytes during B cell differentiation. Cell and Tissue Research, 2016, 363, 411-426.	2.9	15
20	O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. Oncotarget, 2016, 7, 83570-83587.	1.8	38
21	Abstract 2408: Melatonin action in xenograft model of breast cancer, comparing radiopharmaceuticals in the detection of intratumor heterogeneity by PET/CT confirmed by immunohistochemical markers., 2016,,.		0
22	Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice. BMC Immunology, 2015, 16, 68.	2.2	5
23	Candida albicans phospholipomannan: a sweet spot for controlling host response/inflammation. Seminars in Immunopathology, 2015, 37, 123-130.	6.1	14
24	Nanoradiopharmaceuticals for Bone Cancer Metastasis Imaging. Current Cancer Drug Targets, 2015, 15, 445-449.	1.6	5
25	Galectinâ€3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGF β 1â€induced macrophages. Cancer Medicine, 2014, 3, 201-214.	2.8	42
26	Galectinâ€3 negatively regulates the frequency and function of <scp>CD</scp> 4 ⁺ <scp>CD</scp> 25 ⁺ <scp>F</scp> oxp3 ⁺ regulatory <scp>T</scp> cells and influences the course of <i><scp>L</scp>eishmania major</i> infection. European Journal of Immunology, 2013, 43, 1806-1817.	2.9	41
27	Monocyte Migration Driven by Galectin-3 Occurs through Distinct Mechanisms Involving Selective Interactions with the Extracellular Matrix. ISRN Inflammation, 2013, 2013, 1-9.	4.9	20
28	Deficient Beta-Mannosylation of Candida albicans Phospholipomannan Affects the Proinflammatory Response in Macrophages. PLoS ONE, 2013, 8, e84771.	2.5	16
29	Oropouche virus experimental infection in the golden hamster (Mesocrisetus auratus). Virus Research, 2011, 155, 35-41.	2.2	22
30	Galectin-3 expression: a useful tool in the differential diagnosis of posterior fossa tumors in children. Child's Nervous System, 2011, 27, 253-257.	1.1	8
31	LPS-Induced Galectin-3 Oligomerization Results in Enhancement of Neutrophil Activation. PLoS ONE, 2011, 6, e26004.	2.5	78
32	Sialylation regulates galectin-3/ligand interplay during mammary tumour progression - a case of targeted uncloaking. International Journal of Developmental Biology, 2011, 55, 823-834.	0.6	24
33	Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology, 2010, 20, 1341-1352.	2.5	30
34	Lack of Galectin-3 Drives Response to Paracoccidioides brasiliensis toward a Th2-Biased Immunity. PLoS ONE, 2009, 4, e4519.	2.5	49
35	Galectin-3 regulates peritoneal B1-cell differentiation into plasma cells. Glycobiology, 2009, 19, 1248-1258.	2.5	42
36	Neutrophil activation induced by ArtinM: Release of inflammatory mediators and enhancement of effector functions. Immunology Letters, 2009, 123, 14-20.	2.5	40

#	Article	IF	CITATION
37	Azithromycin Reduces Ocular Infection During Congenital Transmission of Toxoplasmosis in the Calomys callosus Model. Journal of Parasitology, 2009, 95, 1005-1010.	0.7	15
38	Lack of galectinâ€3 alters the balance of innate immune cytokines and confers resistance to <i>Rhodococcus equi</i> infection. European Journal of Immunology, 2008, 38, 2762-2775.	2.9	43
39	Evidence for glycosylation on a DNA-binding protein of Salmonella enterica. Microbial Cell Factories, 2007, 6, 11.	4.0	10
40	Neutrophil haptotaxis induced by mouse MNCF: interactions with extracellular matrix glycoproteins probably contribute to overcoming the anti-inflammatory action of dexamethasone. Inflammation Research, 2007, 56, 368-376.	4.0	8
41	Toxoplasma gondii Infection Reveals a Novel Regulatory Role for Galectin-3 in the Interface of Innate and Adaptive Immunity. American Journal of Pathology, 2006, 168, 1910-1920.	3.8	109
42	Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Microbes and Infection, 2006, 8, 1244-1251.	1.9	67
43	Isolation, purification, and physicochemical characterization of a d-galactose-binding lectin from seeds of Erythrina speciosa. Archives of Biochemistry and Biophysics, 2003, 410, 222-229.	3.0	49